This led to the accelerated clinical studies using anti-PD1/PDL-1 antibodies and regulatory approval in other malignancies including few hematological malignancies, non-small cell lung cancer (NSCLC), and melanoma (4, 5). The gene discussed is CD274; the disease is non-small cell lung carcinoma.